Citigroup
PYXS icon

Citigroup’s Pyxis Oncology PYXS Stock Holding History

Citigroup’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
38,205
+36,465
+2,096% +$69.7K ﹤0.01% 4597
2026
Q1 		$2.54K Sell
1,740
-1,162
-40% -$1.75K ﹤0.01% 5396
2025
Q4 		$3.34K Buy
2,902
+1,621
+127% +$5.72K ﹤0.01% 5356
2025
Q3 		$2.84K Sell
1,281
-7,646
-86% -$11K ﹤0.01% 5403
2025
Q2 		$9.82K Sell
8,927
-26,113
-75% -$29.4K ﹤0.01% 5190
2025
Q1 		$34.3K Sell
35,040
-7,048
-17% -$9.4K ﹤0.01% 4984
2024
Q4 		$65.7K Buy
42,088
+6,513
+18% +$18.8K ﹤0.01% 5002
2024
Q3 		$131K Buy
35,575
+24,613
+225% +$86.1K ﹤0.01% 4630
2024
Q2 		$36.3K Sell
10,962
-33,733
-75% -$142K ﹤0.01% 4766
2024
Q1 		$190K Buy
+44,695
New +$188K ﹤0.01% 4046
2023
Q1 		– Sell
-357,537
Closed -$479K – 5787
2022
Q4 		$479K Buy
357,537
+45,229
+14% +$67.9K ﹤0.01% 3207
2022
Q3 		$615K Sell
312,308
-103
-0% -$269 ﹤0.01% 3088
2022
Q2 		$744K Buy
312,411
+79,282
+34% +$211K ﹤0.01% 2917
2022
Q1 		$942K Buy
233,129
+229,923
+7,172% +$1.68M ﹤0.01% 3028
2021
Q4 		$35K Buy
+3,206
New +$36.7K ﹤0.01% 5224

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's PYXS Position: Q2 2026 in Review

Citigroup increased its Pyxis Oncology (PYXS) stake by 2,096% in Q2 2026, buying an estimated $69.7K and bringing the position to 38,205 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #4597.

Citigroup first reported a position in PYXS in Q4 2021 and has held it in 15 quarters since. The position peaked at $942K in Q1 2022. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Citigroup held 38,205 shares of Pyxis Oncology worth $115K as of Q2 2026.
  • Citigroup bought 36,465 Pyxis Oncology shares in Q2 2026, an estimated $69.7K.
  • Pyxis Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4597 holding.
  • Citigroup first reported a position in Pyxis Oncology in Q4 2021 and has held it in 15 quarters since.
  • Citigroup's Pyxis Oncology position peaked at $942K in Q1 2022.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.